The authors found that decitabine, a DNA methyltransferase inhibitor, could sensitize gefitinib response, resulting in inhibition of tumor cell growth and apoptosis, as well as decreased EGFR protein expression [4,97]. The gene discussed is EGFR; the disease is neoplasm.